ad image

Company Info

Wheeler Bio

Wheeler Bio

CDMO

Overview

Wheeler Bio is a biomanufacturing company designed to accelerate the translation of therapeutic innovation into clinical impact. Through parallel integration with pre-clinical discovery, Wheeler is democratizing access to comprehensive discovery-to-IND programs with its rapid, high-quality biomanufacturing and Portable CMC™ platform. With an initial focus on antibody therapeutics, the company is partnered with Alloy Therapeutics to offer emerging biopharma companies a faster and more predictable path to the clinic by avoiding the critical gaps between discovery and early development. Wheeler’s unique partnering model is built on shared success, creating a singular focus on quality, speed, and lasting collaborations. Wheeler Bio is headquartered in Oklahoma City with pilot labs located inside Alloy Therapeutics’ Boston, MA Facility.
Wheeler Bio
Contributions
21 Contributions1 / 2
Wheeler Bio
CDMO

Wheeler Bio Licenses ATUM’s miFuc Technology to Expand Their Portable CMC Platform Capabilities

Wheeler Bio

PR-09-24-NI-14Sep 24, 2024
Rethinking the Conventional CDMO Model
CDMO Model

Rethinking the Conventional CDMO Model

Wheeler Bio

PAO-08-24-CL-04Jul 29, 2024
Overcoming Development Challenges with Digital Solutions
Digitalization

Overcoming Development Challenges with Digital Solutions

Wheeler Bio

PAO-06-24-CL-06Jul 02, 2024
Leveraging Innovative Transposase Technology for a Highly Reliable and Productive CMC Platform
Leap-In Transposase

Leveraging Innovative Transposase Technology for a Highly Reliable and Productive CMC Platform

Wheeler Bio

PAO-06-24-CL-05May 30, 2024
How Synergistic Collaborations Between Outsourcing Partners Can Accelerate Clinical Success
The PHASE Platform

How Synergistic Collaborations Between Outsourcing Partners Can Accelerate Clinical Success

Wheeler Bio

PAO-05-24-CL-01May 08, 2024
Wheeler Bio
Portable CMC

Wheeler Bio Seals Agreement with Charles River to Offer Portable CMC® to Discovery Clients to Accelerate Their Journey to First-in-Human Use

Wheeler Bio

PR-M02-29-01Feb 29, 2024
Revolutionizing Early-Stage Biopharma Development: Introducing Wheeler Bio's Portable CMC® Platform
CMC

Revolutionizing Early-Stage Biopharma Development: Introducing Wheeler Bio's Portable CMC® Platform

Wheeler Bio

PAO-12-23-CL-04Feb 08, 2024
Rethinking the Pharma/Biopharma Supply Chain to Maximize Resilience
Supply Chain

Rethinking the Pharma/Biopharma Supply Chain to Maximize Resilience

Tim Tyson; Jesse McCool, Ph.D.; Russell Harris; Yongkwan Ma

TriRx Pharmaceutical Services

PTV-12-23-CL-02Dec 12, 2023
Wheeler Bio

Alloy Therapeutics and Wheeler Bio Announce Preferred Service Offering for Alloy Partners to Accelerate the Translation from Discovery to CMC

Wheeler Bio

PR-M11-23-01Nov 08, 2023
Wheeler Bio

Wheeler Bio Announces Grand Opening of Biomanufacturing Facility

Wheeler Bio

PR-M10-23-01Oct 05, 2023
Wheeler Bio
Business Leadership

Wheeler Bio Appoints Marc Helouin as Chief Quality and Regulatory Officer

Wheeler Bio

PR-M08-23-01Aug 15, 2023
The Biopharma Industry is Well Prepared for an Overhaul of the Lead-to-Clinic CMC Process for Antibodies
CMC

The Biopharma Industry is Well Prepared for an Overhaul of the Lead-to-Clinic CMC Process for Antibodies

Jesse McCool, Ph.D.; David Schmidt, M.B.A., M.Sc.; Oren Beske, Ph.D.; Stephen Monks, Ph.D.

Wheeler Bio

PAO-07-23-CL-05Jul 26, 2023
Wheeler Bio
Leadership

Wheeler Bio Appoints Dr. Stewart McNaull as Chief Business Officer

Wheeler Bio

PR-M06-23-02Jun 06, 2023
Wheeler Bio
Biologics Testing Lab

Wheeler Bio and Charles River Laboratories Announce Agreement to Build and Operate RightSource℠ Laboratory

Wheeler Bio

PR-M06-23-01May 31, 2023
Wheeler Bio
Cell Line Development Technology

Wheeler Bio Licenses ATUM’s Proprietary Leap-In Transposase® Technology in Support of its Disruptive CDMO Service Offering

Wheeler Bio

PR-M11-22-09Nov 30, 2022
Wheeler Bio
Series A Funding

Wheeler Bio Announces Initial Closing of Series A Round Supporting New Biologics Drug Substance GMP Expansion In Oklahoma

Wheeler Bio

PR-M10-22-02Oct 05, 2022
Wheeler Bio
Leadership

Wheeler Bio Announces Roger Lias, Ph.D. as President and Chief Operating Officer

Wheeler Bio

PR-M09-22-05Sep 22, 2022
Applying an Advanced Pharma 4.0 Perspective to Design the Facility of the Future
Pharma 4.0

Applying an Advanced Pharma 4.0 Perspective to Design the Facility of the Future

Yuk Chun Chiu, M.S.E.; Dawn Wofford; Patricia Robbins; Yvonne Duckworth; Steve Attig

Wheeler Bio

PAO-06-022-CL-11Sep 08, 2022
Integrating Cell Line and CMC Development
Cell Line Development

Integrating Cell Line and CMC Development

Stephen Hamilton, Ph.D.; Mike Brem

Wheeler Bio

PAO-06-022-CL-12Sep 02, 2022
Reducing Time to IND, Increasing Quality, and Building Trust through Shared Data
Digitalization

Reducing Time to IND, Increasing Quality, and Building Trust through Shared Data

David Alvaro, Ph.D.; Christa Short; Jesse McCool, Ph.D.; Lance Johnson; Markus Gershater, Ph.D.; Michael Sokolov, Ph.D.; Yuk Chun Chiu, M.S.E.; Guy Levy-Yurista, Ph.D.; David Schmidt, M.B.A., M.Sc.

Pharma's Almanac

PAO-05-022-CL-01May 18, 2022
1 / 2